Next Article in Journal
Understanding the Needs of Veterans with PTSD
Next Article in Special Issue
Neuropsychiatric Lyme Borreliosis: An Overview with a Focus on a Specialty Psychiatrist’s Clinical Practice
Previous Article in Journal
Orthopedic Professionals’ Recognition and Knowledge of Pain and Perceived Barriers to Optimal Pain Management at Five Hospitals
Previous Article in Special Issue
Far-Reaching Dispersal of Borrelia burgdorferi Sensu Lato-Infected Blacklegged Ticks by Migratory Songbirds in Canada
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessArticle
Healthcare 2018, 6(3), 99; https://doi.org/10.3390/healthcare6030099

Pilot Study of Immunoblots with Recombinant Borrelia burgdorferi Antigens for Laboratory Diagnosis of Lyme Disease

1
ID-FISH Technology Inc., 797 San Antonio Road, Palo Alto, CA 94303, USA
2
IGeneX Inc., 795 San Antonio Road, Palo Alto, CA 94303, USA
*
Author to whom correspondence should be addressed.
Received: 17 May 2018 / Revised: 7 August 2018 / Accepted: 10 August 2018 / Published: 14 August 2018
Full-Text   |   PDF [872 KB, uploaded 21 August 2018]   |  

Abstract

Accurate laboratory diagnosis of Lyme disease (Lyme borreliosis), caused by the spirochete Borrelia burgdorferi (BB), is difficult and yet important to prevent serious disease. The US Centers for Disease Control and Prevention (CDC) presently recommends a screening test for serum antibodies followed by confirmation with a more specific Western blot (WB) test to detect IgG and IgM antibodies against antigens in whole cell lysates of BB. Borrelia species related to BB cause tick-borne relapsing fever (TBRF). TBRF is increasingly recognized as a health problem in the US and occurs in areas where Lyme disease is prevalent. The two groups of Borrelia share related antigens. We have developed a modified WB procedure termed the Lyme immunoblots (IBs) using recombinant antigens from common strains and species of the BB sensu lato complex for serological diagnosis of Lyme disease. A reference collection of 178 sera from 26 patients with and 152 patients without Lyme disease were assessed by WB and IB in a blinded manner using either criteria for positive antibody reactions recommended by the CDC or criteria developed in-house. The sensitivity, specificity, positive and negative predictive values obtained with the reference sera suggest that the Lyme IB is superior to the Lyme WB for detection of specific antibodies in Lyme disease. The Lyme IB showed no significant reaction with rabbit antisera produced against two Borrelia species causing TBRF in the US, suggesting that the Lyme IB may be also useful for excluding TBRF. View Full-Text
Keywords: Borrelia burgdorferi; immunoblot; laboratory diagnosis; Lyme disease; tick-borne diseases; western blot Borrelia burgdorferi; immunoblot; laboratory diagnosis; Lyme disease; tick-borne diseases; western blot
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Liu, S.; Cruz, I.D.; Ramos, C.C.; Taleon, P.; Ramasamy, R.; Shah, J. Pilot Study of Immunoblots with Recombinant Borrelia burgdorferi Antigens for Laboratory Diagnosis of Lyme Disease. Healthcare 2018, 6, 99.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Healthcare EISSN 2227-9032 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top